Matthew McAviney is a Partner at New Enterprise Associates (NEA) on the healthcare team. See sector focus and contact routes.
Matthew McAviney is a Partner at New Enterprise Associates (NEA) on the healthcare team, focusing specifically on biopharma investments since joining the firm in 2018. His investment thesis targets transformative healthcare opportunities across Seed, Series A, and select Series B stages, primarily within the biopharma sector. McAviney typically invests in check sizes ranging from $2.0 million to $50.0 million, leveraging his dual expertise as a practicing physician (M.D.) and MBA graduate to evaluate therapeutic ventures. Notable portfolio companies he has supported include AviadoBio, Apellis, Denali, and Semma, the latter of which he helped build during his prior role as a Principal at F-Prime Capital. His distinctive point of view stems from over a decade of experience spanning medicine, equity research at Robert W. Baird, and healthcare strategy consulting at Oliver Wyman, giving him a unique perspective on new therapeutic opportunities. McAviney is based in San Francisco, California, rather than Cambridge, Massachusetts, applying his background in lipid metabolism research and clinical practice to identify high-impact biopharma deals.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Cambridge.
Investors like Matthew McAviney · Full investor directory · Investor access · Company funding database